Zymeworks Inc
(NAS:ZYME)
$
11.53
-0.01 (-0.09%)
Market Cap: 818.47 Mil
Enterprise Value: 509.81 Mil
PE Ratio: 0
PB Ratio: 2.01
GF Score: 80/100 - Q1 2024 Zymeworks Inc Earnings Call TranscriptMay 02, 2024$9 (+2.74%)Earnings
- Q4 2023 Zymeworks Inc Earnings Call TranscriptMar 06, 2024$12.23 (+2.09%)Earnings
- Zymeworks Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2024
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Zymeworks Inc Earnings Call TranscriptNov 07, 2023$7.37 (+1.24%)Earnings
- Zymeworks Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Zymeworks Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Zymeworks Inc Earnings Call TranscriptAug 10, 2023$7.76 (+0.78%)Earnings
- Zymeworks Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Zymeworks Inc Earnings Call TranscriptMay 08, 2023$8.76 (+1.39%)Earnings
- Zymeworks Inc Investor Call TranscriptApr 18, 2023
- Zymeworks Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Zymeworks Inc Earnings Call TranscriptMar 07, 2023$7.96 (+0.13%)Earnings
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Zymeworks Inc HERIZON-BTC-01 Top-Line Results Call TranscriptDec 19, 2022
Zymeworks Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023 / 03:55PM GMT
Release Date Price:
$9.98
(+2.99%)
Jason Eron Zemansky
BofA Securities, Research Division - VP
Good afternoon. Thank you so much for joining us. My name is Jason Zemansky. I'm one of the new SMID cap biotech analyst here at BofA, welcoming everyone to this, our final morning. Very pleased to be able to introduce Zymeworks and the Chair and CEO, Ken Galbraith, which is here with us today. Ken, thank you so much for joining me.
Kenneth H. Galbraith
Zymeworks Inc. - CEO & Chairman of the Board
No, Jason, thanks for the invitation to come to Las Vegas and attend your conference.
Questions & Answers
Jason Eron Zemansky;Kenneth H. Galbraith
BofA Securities, Research Division - VP;Zymeworks Inc. - CEO &
Wonderful. Well, maybe let's start off a little bit more broadly for those who maybe aren't as familiar with the story and the platform. Can you talk a little bit about your platform, what separates your multi-specific antibody technology from competitors? And how is the ADC platform differentiated?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)